Arovella Therapeutics (ASX: ALA) is an Australian-listed company in the Healthcare sector with a market capitalisation of $85.8M and the 863rd-largest security on the ASX by market capitalisation. The ALA share price is $0.071, down 1.39% today and down 26.04% over the past 12 months. Shares have traded between $0.065 and $0.125 over the past 52 weeks. In its most recent reported period (ending 31 Dec 2025), Arovella Therapeutics reported revenue of $0 and a net loss of $1.9M.
About Arovella Therapeutics Limited
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
